Martine Grosber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martine Grosber has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Pieter Cornu
Research Centre for Digital Medicine, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, 1090 Brussels, Belgium
2 shared publications - Sven Van Laere
Department of Radiotherapy, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
2 shared publications A. Tache
European Face Centre Cleft & Craniofacial Team Universitair Ziekenhuis Brussel (UZB) Brussels Belgium
1 shared publication- F. Mana
Department of Gastro‐enterology Saint‐Jean Clinic Brussels Belgium
1 shared publication - Fariza Mishaal Saiema Badloe
Vrije Universiteit Brussel (VUB) Skin Immunology & Immune Tolerance (SKIN) Research Group Brussels Belgium
1 shared publication Inge Kortekaas Krohn
SKIN Research Group Vrije Univeristeit Brussel (VUB) Brussels Belgium
1 shared publication
Latest Publications
- 25 October 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (3) , 281-284
Managing Drug Hypersensitivities: Clinicians' Perceptions on an Optimised Documentation Tool With De‐Labelling Feature
- 25 October 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (3) , 281-284
Managing Drug Hypersensitivities: Clinicians' Perceptions on an Optimised Documentation Tool With De‐Labelling Feature
- 29 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (11) , 2082-2092
Treatment of acute urticaria: A systematic review
There are only a few clinical trials which address the treatment of acute urticaria (AU). Especially, the added value of systemic corticosteroids to antihistamines is unclear in treatment of severe AU. To review the existing evidence‐based approaches for AU treatment. A systematic electronic search was done in PubMed and Web of Science to retrieve all studies on the treatment of patients with AU. A descriptive synthesis was conducted based on the PRISMA statement. Quality assessment was independently performed by both reviewers (‘Cochrane risk‐of‐bias tool’ for RCTs). Ten randomized controlled trials (RCTs) (n = 857 participants) were included. Four studies assessed corticosteroid effectiveness added to antihistamines and six studies compared the efficacy of H1 and/ or H2‐antihistamines. The addition of corticosteroid (prednisone) to an antihistamine (levo)cetirizine did not improve symptoms of AU compared to antihistamine alone in two out of three RCTs. The combination of diphenhydramine (50 mg, IV) and ranitidine (50 mg, IV) or cimetidine (300 mg, IV) was most efficient for relief of urticaria in two out of five studies. Most frequent adverse effects were sedation and drowsiness. Recent guidelines on urticaria treatment mainly focus on chronic urticaria rather than on AU. Moreover, only few, small RCTs provide evidence for the management of AU. Thus, the state‐of‐the‐art management of this frequent condition remains unclear. The addition of corticosteroids to an antihistamine as treatment for AU needs to be further investigated. Well‐designed, high‐quality interventional trials are needed to establish evidence‐based treatment guidelines for AU.
- 29 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (11) , 2082-2092
Treatment of acute urticaria: A systematic review
There are only a few clinical trials which address the treatment of acute urticaria (AU). Especially, the added value of systemic corticosteroids to antihistamines is unclear in treatment of severe AU. To review the existing evidence‐based approaches for AU treatment. A systematic electronic search was done in PubMed and Web of Science to retrieve all studies on the treatment of patients with AU. A descriptive synthesis was conducted based on the PRISMA statement. Quality assessment was independently performed by both reviewers (‘Cochrane risk‐of‐bias tool’ for RCTs). Ten randomized controlled trials (RCTs) (n = 857 participants) were included. Four studies assessed corticosteroid effectiveness added to antihistamines and six studies compared the efficacy of H1 and/ or H2‐antihistamines. The addition of corticosteroid (prednisone) to an antihistamine (levo)cetirizine did not improve symptoms of AU compared to antihistamine alone in two out of three RCTs. The combination of diphenhydramine (50 mg, IV) and ranitidine (50 mg, IV) or cimetidine (300 mg, IV) was most efficient for relief of urticaria in two out of five studies. Most frequent adverse effects were sedation and drowsiness. Recent guidelines on urticaria treatment mainly focus on chronic urticaria rather than on AU. Moreover, only few, small RCTs provide evidence for the management of AU. Thus, the state‐of‐the‐art management of this frequent condition remains unclear. The addition of corticosteroids to an antihistamine as treatment for AU needs to be further investigated. Well‐designed, high‐quality interventional trials are needed to establish evidence‐based treatment guidelines for AU.
- Open Access
- 6 April 2022
- Published by Wiley in Clinical and Translational Allergy
- Vol. 12 (4) , e12141
Physicians' needs for drug allergy documentation in electronic health records and allergy alert systems: Results of an end user's survey
- 6 April 2022
- Published by Wiley in Clinical and Translational Allergy
- Vol. 12 (4) , e12141
Open AccessPhysicians' needs for drug allergy documentation in electronic health records and allergy alert systems: Results of an end user's survey
- 25 September 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (3) , E236-E237
Oral tuberculosis in a patient with Crohn's disease on TNF‐α blockers
- 25 September 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (3) , E236-E237
Oral tuberculosis in a patient with Crohn's disease on TNF‐α blockers